Effect of depot medroxyprogesterone acetate on postpartum depression

Rita Tsai, Jonathan Schaffir

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Depot medroxyprogesterone acetate (DMPA) is commonly prescribed to women immediately postpartum due to its efficacy, convenience and lack of estrogen. It is unclear whether administering a progestin injection can affect the course of postpartum depression (PPD), which some suspect to be influenced by hormonal changes. In this retrospective study, the objective was to determine whether DMPA administered immediately postpartum influences the development of PPD. Study Design: A retrospective review of a total of 404 charts was conducted of clinic patients who were scheduled for 6-week postpartum visits at a major medical center, where all patients are routinely asked to complete the Edinburgh Postnatal Depression Scale (EPDS). The average scores on the EPDS at these visits were compared between patients who had received DMPA prior to postpartum discharge from the hospital and patients who had not received any hormonal contraception by using an unpaired t test. In addition, the proportions of women diagnosed with PPD via the scale were compared via contingency tables. Results: Fifty-five women who had received immediate DMPA were compared with 192 women with no hormonal contraception after delivery. The groups were similar in parity, race, mode of delivery and weight, but women receiving DMPA were significantly younger (24.2 vs. 26.2 years, p=.03). Mean EPDS scores at 6 weeks postpartum were not statistically significant between the groups (5.02 vs. 6.17, p=.16). Six patients (10.9%) who received immediate DMPA were diagnosed with PPD based on EPDS scores greater than or equal to 13, while 27 (14.1%) in the comparison group had PPD (p=.88). Conclusion: Administration of DMPA in the immediate postpartum period does not appear to predispose women to PPD.

Original languageEnglish (US)
Pages (from-to)174-177
Number of pages4
JournalContraception
Volume82
Issue number2
DOIs
StatePublished - Aug 2010

Fingerprint

Postpartum Depression
Medroxyprogesterone Acetate
Postpartum Period
Contraception
Patient Discharge
Progestins
Parity
Estrogens
Retrospective Studies
Weights and Measures

Keywords

  • Contraception
  • Depo-Provera
  • DMPA
  • Postpartum depression
  • Progesterone

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology
  • Medicine(all)

Cite this

Effect of depot medroxyprogesterone acetate on postpartum depression. / Tsai, Rita; Schaffir, Jonathan.

In: Contraception, Vol. 82, No. 2, 08.2010, p. 174-177.

Research output: Contribution to journalArticle

Tsai, Rita ; Schaffir, Jonathan. / Effect of depot medroxyprogesterone acetate on postpartum depression. In: Contraception. 2010 ; Vol. 82, No. 2. pp. 174-177.
@article{b80d1af353ed4546ae739aa91f715f4e,
title = "Effect of depot medroxyprogesterone acetate on postpartum depression",
abstract = "Background: Depot medroxyprogesterone acetate (DMPA) is commonly prescribed to women immediately postpartum due to its efficacy, convenience and lack of estrogen. It is unclear whether administering a progestin injection can affect the course of postpartum depression (PPD), which some suspect to be influenced by hormonal changes. In this retrospective study, the objective was to determine whether DMPA administered immediately postpartum influences the development of PPD. Study Design: A retrospective review of a total of 404 charts was conducted of clinic patients who were scheduled for 6-week postpartum visits at a major medical center, where all patients are routinely asked to complete the Edinburgh Postnatal Depression Scale (EPDS). The average scores on the EPDS at these visits were compared between patients who had received DMPA prior to postpartum discharge from the hospital and patients who had not received any hormonal contraception by using an unpaired t test. In addition, the proportions of women diagnosed with PPD via the scale were compared via contingency tables. Results: Fifty-five women who had received immediate DMPA were compared with 192 women with no hormonal contraception after delivery. The groups were similar in parity, race, mode of delivery and weight, but women receiving DMPA were significantly younger (24.2 vs. 26.2 years, p=.03). Mean EPDS scores at 6 weeks postpartum were not statistically significant between the groups (5.02 vs. 6.17, p=.16). Six patients (10.9{\%}) who received immediate DMPA were diagnosed with PPD based on EPDS scores greater than or equal to 13, while 27 (14.1{\%}) in the comparison group had PPD (p=.88). Conclusion: Administration of DMPA in the immediate postpartum period does not appear to predispose women to PPD.",
keywords = "Contraception, Depo-Provera, DMPA, Postpartum depression, Progesterone",
author = "Rita Tsai and Jonathan Schaffir",
year = "2010",
month = "8",
doi = "10.1016/j.contraception.2010.03.004",
language = "English (US)",
volume = "82",
pages = "174--177",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Effect of depot medroxyprogesterone acetate on postpartum depression

AU - Tsai, Rita

AU - Schaffir, Jonathan

PY - 2010/8

Y1 - 2010/8

N2 - Background: Depot medroxyprogesterone acetate (DMPA) is commonly prescribed to women immediately postpartum due to its efficacy, convenience and lack of estrogen. It is unclear whether administering a progestin injection can affect the course of postpartum depression (PPD), which some suspect to be influenced by hormonal changes. In this retrospective study, the objective was to determine whether DMPA administered immediately postpartum influences the development of PPD. Study Design: A retrospective review of a total of 404 charts was conducted of clinic patients who were scheduled for 6-week postpartum visits at a major medical center, where all patients are routinely asked to complete the Edinburgh Postnatal Depression Scale (EPDS). The average scores on the EPDS at these visits were compared between patients who had received DMPA prior to postpartum discharge from the hospital and patients who had not received any hormonal contraception by using an unpaired t test. In addition, the proportions of women diagnosed with PPD via the scale were compared via contingency tables. Results: Fifty-five women who had received immediate DMPA were compared with 192 women with no hormonal contraception after delivery. The groups were similar in parity, race, mode of delivery and weight, but women receiving DMPA were significantly younger (24.2 vs. 26.2 years, p=.03). Mean EPDS scores at 6 weeks postpartum were not statistically significant between the groups (5.02 vs. 6.17, p=.16). Six patients (10.9%) who received immediate DMPA were diagnosed with PPD based on EPDS scores greater than or equal to 13, while 27 (14.1%) in the comparison group had PPD (p=.88). Conclusion: Administration of DMPA in the immediate postpartum period does not appear to predispose women to PPD.

AB - Background: Depot medroxyprogesterone acetate (DMPA) is commonly prescribed to women immediately postpartum due to its efficacy, convenience and lack of estrogen. It is unclear whether administering a progestin injection can affect the course of postpartum depression (PPD), which some suspect to be influenced by hormonal changes. In this retrospective study, the objective was to determine whether DMPA administered immediately postpartum influences the development of PPD. Study Design: A retrospective review of a total of 404 charts was conducted of clinic patients who were scheduled for 6-week postpartum visits at a major medical center, where all patients are routinely asked to complete the Edinburgh Postnatal Depression Scale (EPDS). The average scores on the EPDS at these visits were compared between patients who had received DMPA prior to postpartum discharge from the hospital and patients who had not received any hormonal contraception by using an unpaired t test. In addition, the proportions of women diagnosed with PPD via the scale were compared via contingency tables. Results: Fifty-five women who had received immediate DMPA were compared with 192 women with no hormonal contraception after delivery. The groups were similar in parity, race, mode of delivery and weight, but women receiving DMPA were significantly younger (24.2 vs. 26.2 years, p=.03). Mean EPDS scores at 6 weeks postpartum were not statistically significant between the groups (5.02 vs. 6.17, p=.16). Six patients (10.9%) who received immediate DMPA were diagnosed with PPD based on EPDS scores greater than or equal to 13, while 27 (14.1%) in the comparison group had PPD (p=.88). Conclusion: Administration of DMPA in the immediate postpartum period does not appear to predispose women to PPD.

KW - Contraception

KW - Depo-Provera

KW - DMPA

KW - Postpartum depression

KW - Progesterone

UR - http://www.scopus.com/inward/record.url?scp=77955713138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955713138&partnerID=8YFLogxK

U2 - 10.1016/j.contraception.2010.03.004

DO - 10.1016/j.contraception.2010.03.004

M3 - Article

C2 - 20654759

AN - SCOPUS:77955713138

VL - 82

SP - 174

EP - 177

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 2

ER -